SCPH Share Price Performance
US$5.67
2.13 (60.17%)
77.3% undervalued intrinsic discount
US$25.00
Fair Value
Price US$5.67
AnalystHighTarget US$25.00
AnalystConsensusTarget US$12.12
AnalystLowTarget US$5.35
Fair ValueUS$25.00
Share Pricen/a
scPharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
SCPH Community Narratives
AN
Fair Value US$25 77.3% undervalued intrinsic discount
Accelerated At-Home Care Will Drive FUROSCIX And sc2Wear Adoption
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$12.12 53.2% undervalued intrinsic discount
Outpatient Care Shift And Medicare Redesign Will Expand Patient Access
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$5.35 6.0% overvalued intrinsic discount
Inflation Reduction Act And Biosimilars Will Undermine Pricing Power
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Accelerated At-Home Care Will Drive FUROSCIX And sc2Wear Adoption
Key Takeaways Rapid adoption and expanded use of FUROSCIX, alongside the auto-injector and sc2Wear™ platform, could dramatically outperform current market expectations. Strategic partnerships and industry trends toward outpatient, value-based care position the company for robust, recurring growth in chronic disease management.Read more
8
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$25
77.3% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
82.47% p.a.
Profit Margin
39.06%
Future PE
16.42x
Price in 2028
US$30.24
Outpatient Care Shift And Medicare Redesign Will Expand Patient Access
Key Takeaways Rapid adoption of FUROSCIX, Medicare changes, and expansion into new care settings are likely to accelerate growth and broaden the patient base. Cost-saving auto-injector launch and deeper sales network penetration should improve margins, ensure wider product uptake, and promote recurring revenues.Read more
54
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$12.12
53.2% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
62.35% p.a.
Profit Margin
25.3%
Future PE
17.45x
Price in 2028
US$14.66
Inflation Reduction Act And Biosimilars Will Undermine Pricing Power
Key Takeaways Heavy dependence on FUROSCIX exposes the company to major risks from regulatory, pricing, and competitive shifts that could sharply impact earnings. Profitability remains challenged by rising operational costs, healthcare payer pressures, and increased competition from generics and biosimilars.Read more
3
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$5.35
6.0% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
56.18% p.a.
Profit Margin
13.04%
Future PE
16.79x
Price in 2028
US$6.47
Trending Discussion
Recently Updated Narratives
AN
Inflation Reduction Act And Biosimilars Will Undermine Pricing Power
Fair Value: US$5.35 6.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Accelerated At-Home Care Will Drive FUROSCIX And sc2Wear Adoption
Fair Value: US$25 77.3% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Outpatient Care Shift And Medicare Redesign Will Expand Patient Access
Fair Value: US$12.12 53.2% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
scPharmaceuticals Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -1.71
- 68.46%
- -183.55%
- -240.2%
About SCPH
- Founded
- 2013
- Employees
- 163
- CEO
- WebsiteView website
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. Its product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity and drug-device combination product candidate consisting of a prefilled syringe containing SCP-111 preloaded into a mechanical autoinjector. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
